Home › Funds › Logos Global Management LP › DSGN
Logos Global Management LP position in DSGN
DESIGN THERAPEUTICS INC · Health Care
Logos Global Management LP reported holding 1,000,000 shares of DSGN (DESIGN THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$12.6M, representing 0.76% of its reported portfolio and ranking #39 among its reported holdings. Logos Global Management LP has disclosed DSGN holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How Logos Global Management LP's DSGN position evolved
Logos Global Management LP first disclosed a stake in DSGN in Q3 2023 at 5,032,501 shares (US$11.9M). The position peaked in Q2 2026 at 3,000,000 shares, worth US$43.4M. Across 13 filings, Logos Global Management LP increased the stake 1 time(s), trimmed it 5 time(s) and left it unchanged 6 time(s). The most recent filing (Q3 2026) shows 1,000,000 shares valued at US$12.6M — a reduction of -2,000,000 shares quarter over quarter.. Notable position changes include a 32% trim in Q4 2025 (shares rose 13% over the following quarter), a 54% increase in Q2 2026 (shares fell 13% over the following quarter), a 67% trim in Q3 2026 (shares fell 17% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 5.03M | $11.88M | New |
| Q4 2023 | 5.03M | $13.34M | Hold |
| Q1 2024 | 5.03M | $20.28M | Hold |
| Q2 2024 | 5.03M | $16.86M | Hold |
| Q3 2024 | 4.22M | $22.69M | Reduce |
| Q4 2024 | 4.22M | $26.02M | Hold |
| Q1 2025 | 4.22M | $16.28M | Hold |
| Q2 2025 | 4.22M | $14.21M | Hold |
| Q3 2025 | 3.65M | $27.52M | Reduce |
| Q4 2025 | 2.50M | $23.45M | Reduce |
| Q1 2026 | 1.95M | $20.75M | Reduce |
| Q2 2026 | 3.00M | $43.41M | Add |
| Q3 2026 | 1.00M | $12.57M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About DSGN and 13F data
DSGN (DESIGN THERAPEUTICS INC) is a Health Care company. 42 other funds we track also report a position in DSGN — the largest reported positions include SR ONE CAPITAL MANAGEMENT, LP (US$94.4M), BAKER BROS. ADVISORS LP (US$38.8M), Trails Edge Capital Partners, LP (US$31.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding DSGN
- SR ONE CAPITAL MANAGEMENT, LP 6.53M sh · $94.44M · Q2 2026
- BAKER BROS. ADVISORS LP 2.68M sh · $38.76M · Q2 2026
- Trails Edge Capital Partners, LP 2.50M sh · $31.43M · Q3 2026
- Frazier Life Sciences Management, L.P. 1.81M sh · $26.19M · Q2 2026
- Vivo Capital, LLC 1.61M sh · $20.27M · Q3 2026
- Almitas Capital LLC 1.03M sh · $14.86M · Q2 2026
- Sofinnova Investments, Inc. 1.14M sh · $14.39M · Q3 2026
- KVP Capital Advisors, LP 185.00K sh · $2.33M · Q3 2026
More on Logos Global Management LP
FAQ
How long has Logos Global Management LP held DSGN?
Logos Global Management LP has disclosed DSGN holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Logos Global Management LP's current position in DSGN?
As of Q3 2026, Logos Global Management LP holds 1.00M shares of DSGN (DESIGN THERAPEUTICS INC), valued at $12.57M, representing 0.76% of its reported portfolio and ranking #39.
Has Logos Global Management LP been buying or selling DSGN?
In the latest 13F filing (Q3 2026), Logos Global Management LP reduced its position in DSGN. The position peaked in Q2 2026 at 3.00M shares.
Which other funds hold DSGN?
Other major institutional holders of DSGN include SR ONE CAPITAL MANAGEMENT, LP, BAKER BROS. ADVISORS LP, Trails Edge Capital Partners, LP, among 42 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.